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Population pharmacokinetics of vancomycin in Thai adult patients was determined by non-linear mixed-eﬀects approach using
319 vancomycin serum concentrations from 212 patients. The data were best ﬁtted by a two-compartment model and it was
used to examine the eﬀect of patient characteristics on the vancomycin pharmacokinetics. In the ﬁnal model, there was a linear
relationship between vancomycin clearance, CL (L/h), and creatinine clearance calculated by Cockcroft-Gault equation, CLCr
(mL/min): CL = 0.044 × CLCr. Meanwhile, volume of central compartment, V1 (L), was linearly related with the age (years
old): V1 = 0.542 × Age. Intercompartment clearance (Q) and volume of peripheral compartment (V2) was 6.95L/h and 44.2L,
respectively. The interindividual variability for CL, V1, Q,a n dV2 was 35.78, 20.93, 39.50, and 57.27%, respectively. Whereas, the
intraindividual variability was 4.51mg/L. Final model then was applied to predict serum vancomycin concentrations on validation
group. Predictive performance revealed a bias of −1.43mg/L (95% CI: −5.82–2.99) and a precision of 12.2mg/L (95% CI: −1.60–
26.16). In conclusion, population pharmacokinetic of vancomycin in Thai adult patients was developed. The model could be used
to create vancomycin dosage regimen in the type of patient similar with the present study.
1.Introduction
Vancomycin,anantibioticwithglycopeptidestructure,isone
of a few antibiotics available to treat patients infected with
methicillin-resistant Staphylococcus aureus and methicillin-
resistant coagulase-negative staphylococcal species. Its’ phar-
macokinetics could be changed by the patient conditions
such as renal function [1], age [2], body weight [3], critical
illness [4], type of dialysis [5], and type of infection
[6]. Complexity on using this drug was also raised by
the emergence of vancomycin-intermediate susceptible and
vancomycin-resistant pathogens [7].
In clinical practice, approaches to dosing of vancomycin
include empirical dosing [8] and dosing by nomograms [9,
10]. However, these methods were developed based on phar-
macokinetic parameters derived from a group of Western
population who may have diﬀerent parameter values from
Thai patients. Application of vancomycin nomograms or
dosing methods developed from non-Thai patients in Thai
patients might pose to undesired outcome due to the facts
of narrow therapeutic index and large variability exhibited
by this drug. Present study was performed to elucidate
the pharmacokinetic parameters and factors that may aﬀect
vancomycin pharmacokinetics in Thai population.
2. Methods
Patients with the age of more than 18 years old in any ward
at Ramathibodi Hospital, Mahidol University, Bangkok,
Thailand who received vancomycin with complete data
regarding dosage regimens, serum drug concentration, and
precise timing of dose administration and blood sampling
overtheentirecourseofvancomycintherapyduringJanuary,
2007 till June, 2010 were included. The study protocol was
approved by Human Research Ethics Committee of Faculty
of Medicine, Ramathibodi Hospital, Mahidol University.2 The Scientiﬁc World Journal
Patientsweredividedrandomlyintotwogroups.Theﬁrst
group,asamodelinggroup,wasusedtobuildthepopulation
pharmacokinetic model. After the population model had
been deﬁned, it was used to predict a serum vancomycin
concentration in the second group, a validation group.
Categorical data were analyzed by χ2 test. Continuous data
wereevaluatedfornormalityofdistributionbyKolmogorov-
Smirnov test. Normally distributed continuous data were
analyzed by Student’s t-test or Mann-Whitney U test if the
data were not normally distributed. Diﬀerences between
these groups were considered to reach statistical signiﬁcance
when P<0.05.
Measurement of serum vancomycin concentrations were
conducted as part of therapeutic drug monitoring activ-
ity in the hospital using the ﬂuorescence polarization
immunoassay (FPIA) method with Axsym system. The assay
sensitivity limit was reported to be 2.00mg/L. Furthermore,
the coeﬃcient of variation was 4.26%, 2.94%, and 4.06%
at concentrations of 7.0, 35.0, and 75.0mg/L, respectively
(package insert, Axsym system, Abbot Laboratories, Abbot
P a r k ,I l l ,U S A ) .
2.1. Model Building. Pharmacokinetics (PK) modeling were
developed using NONMEM (nonlinear mixed-eﬀects mod-
eling) software package version VII (Project Group, Uni-
versity of California, San Francisco, Calif, USA). On the
basis of individual data set, a population value of phar-
macokinetic parameters were determined, as ﬁxed-eﬀect
parameters. Additionally, interindividual variability and the
intraindividual variability were estimated as random eﬀects.
To determine the most suitable compartmental model,
datafromvancomycinconcentrationsversustimewereﬁtted
to both one- and two-compartment models, with ﬁrst-
order elimination, speciﬁed to NONMEM by ADVAN1-
TRANS2 or ADVAN3-TRANS4 subroutines, respectively.
The ﬁxed-eﬀect PK parameters estimated directly with
these model speciﬁcations were total body clearance (CL)
and volume of distribution (V) for the one-compartment
model. For the two-compartment model, CL, volume of
distribution of the central compartment (V1), intercom-
partment clearance (Q), and volume of distribution of
the peripheral compartment (V2) were estimated. Additive,
proportional, and exponential-error models were tested
to describe interindividual and intraindividual variabil-
ity.
After basic model was determined, each of covariate
was included one by one to basic model to get covariate
that signiﬁcantly improved the ability of the model to
predicttheobservedconcentration-timeproﬁle(preliminary
screening phase). The covariates of patients were tested for
their inﬂuences on vancomycin pharmacokinetic parameters
as follows: age, gender, weight, serum creatinine concen-
tration, blood urea nitrogen (BUN), creatinine clearance
(usingCockcroft-Gault/C-Gequation[11]andModiﬁcation
of Diet in Renal Disease/MDRD4 equation [12]), serum
albumin concentration, total and direct bilirubin level,
aspartate transaminase (AST) and alanine transaminase
(ALT) level, presence or absence of ascites, and concomitant
drugs (aminoglycosides, amphotericin B, nonsteroidal anti-
inﬂammatory drugs (NSAIDs), dopamine, dobutamine,
adrenaline/noradrenaline,andfurosemide).Then,thesignif-
icant covariates were added cumulatively (forward stepwise
fashion) to the model in the order of their contribution to
the reduction in the objective function value (OFV) in the
preliminary analysis until there was no further reduction in
OFV. Finally, back elimination was conducted to eliminate
any unnecessary covariates from the full regression model
in descending order of their contribution to the change in
OFV.
The best compartment model (one versus two com-
partment), error model (additive versus proportional versus
exponential error models), and the retention of covariate(s)
in the model were determined by statistical signiﬁcance of
the model and evaluated by the likelihood ratio test using the
minimum value of the OFV (−2 log likelihood diﬀerence),
produced by the NONMEM program. Changes in the OFV
>6.63 and >9.21 were determined to be signiﬁcant on the
basis of a χ2 distribution with 1 degree of freedom (χ2, df =
1, P<0.01) and 2 degree of freedom (χ2, df = 2, P<0.01),
respectively.
Otherdiagnosticcriteriawereareductioninunexplained
interindividual variability for the associated PK parameter
and an improvement in the graphic diagnostic model.
Graphics were obtained by plotted observed versus predic-
tive concentrations and observed versus weighted residuals
(predicted minus observed concentration and weighted by
standard deviation).
2.2. Predictive Performance. Population-based parameters
developed from model group were used to predict a value
of vancomycin concentration in the validation group. This
was performed by holding constant the values of the ﬁxed
andrandomeﬀectsparametersoftheﬁnalpopulation model
and running the POSTHOC option in the $ESTIMATION
procedure without allowing NONMEM to iterate. The mean
error (ME) was used to measure bias, while precision was
determined by calculating the mean squared error (MSE)
and the root mean squared error (RMSE). These values with
95% conﬁdence interval for the true mean were estimated
by equation described by Sheiner and Beal [13]. Graphics
were additionally used to determine the deviations between
measured and predicted concentration.
3. Results
Using inclusion criteria described above, 268 patients in total
were included. After randomization, 228 patients belonged
to modeling group and 40 patients to the validation group.
However, in further steps, the numbers of data were reduced
into 212 patients and 34 patients in modeling and validation
group, respectively. In modeling group, the number of
patients was reduced in ﬁnal model, since the covariate
model building processes relied on the availability of partic-
ular covariate within the patients. Meanwhile, the reduced
numberofpatientsinthevalidationgroupoccurred,because
somepatientswererejected,sincetheycouldnotproducetheThe Scientiﬁc World Journal 3
Total number of blood samples
N = 391
First or second dose
N = 146 (37.34%)
Other doses
N = 245 (62.66%)
Blood samples
before next dose
N = 171 (43.73%)
Blood samples
after infusion
N = 61 (15.60%)
Blood samples
drawn other times
N = 159 (40.67%)
drawn <2hours drawn <3hours
Figure 1: Number of vancomycin serum concentrations regarding
to blood sampling time in modeling group.
parameters when POSTHOC option was applied. Then, this
ﬁnal ﬁgure (Table 1) was used in further analysis.
The total number of serum concentrations in modeling
group was 391 samples accounted as 1.84 concentrations per
patient on average (ranging from 1 to 8 samples/patient).
The dosage regimen was varied between patients and within
patient. The serum concentrations in regard to blood
sampling times (peak, trough, and other) also varied as
described in Figure 1.
In the basic model building step (using 432 concentra-
tions from 228 patients), compartment model was com-
pared between one and two compartment. The results pre-
ferred two-compartment model as better model to describe
the present population (the decrease in OFV from one-
compartment to two-compartment model was 154.346; χ2,
df = 2, P<0.01). The error models to describe inter- and
intraindividual variability were inﬂuenced by the nature of
data [14]. In the present study, proportional error model was
best described for interindividual variability, since there was
a large degree of variability in the true parameters. On the
other hand, an additive error model was chosen for intrain-
dividual variability, since the concentrations were within the
narrowrangeofdistribution (89.51%ofconcentrationswere
on range of 2–30mg/L).
In the covariate preliminary screening step, covariates
were divided into three groups on the basis of the similarity
of number of patients who had these covariates. This
approach was implemented, since major diagnostic criteria,
OFV produced by NONMEM, were inﬂuenced by the
amount of data. The less the number of data, the value was
expected to be reduced. In other words, decreasing in OFV
did not always mean the model was a better model when the
number of data was diﬀerent.
The ﬁrst group with 228 patients and 432 levels was
tested for covariates of age, gender, weight, serum creatinine
concentration, and creatinine clearance (using C-G equation
and MDRD4 equation). For vancomycin clearance, three
covariates which reduced OFV more than 6.63 were CLCr
by C-G equation, CLCr by MDRD4 equation, and serum
creatinine concentration. Creatinine clearance from both
equations also became signiﬁcant covariates for volume of
peripheral compartment. Volume of central compartment
was signiﬁcantly aﬀected by creatinine clearance by C-G
equation. Another signiﬁcant covariate was age, which
aﬀected volume of central compartment. Other covariates
(BUN, serum albumin concentration, total and direct biliru-
bin level, AST and ALT level, and presence or absence
of ascites) were tested in 207 patients, using 384 levels.
It revealed that ascites became a signiﬁcant covariate for
volume of central compartment and volume of peripheral
compartment and BUN for vancomycin clearance. Mean-
while,concomitantdrugs(aminoglycosides,amphotericinB,
NSAIDs, dopamine, dobutamine, adrenaline/noradrenaline,
and furosemide) were analysed separately in 216 individuals
with 400 vancomycin levels. Drugs were also combined
and then tested as two groups, which were drugs with
nephrotoxic properties (aminoglycosides, amphotericin B,
NSAIDs, and furosemide) and drugs with haemodynamic
eﬀect (dopamine, dobutamine, adrenaline/noradrenaline,
and furosemide). As a result, there were no single or
combination drugs that signiﬁcantly aﬀected the parameters
in the model.
Before forward stepwise analysis was implemented, those
signiﬁcant covariates were regrouped and combined with
as many as patients who had data for those covariates.
Eventually, 212 patients were chosen and checked for their
contribution to the model, similar manner with process
in preliminary screening phase. Although serum creatinine
generatedasigniﬁcantdecreaseinOFV,itwasomittedinthis
stepsincethecontributionwasmuchlesserthanCLcr by C-G
equation and CLCr by MDRD4 equation.
In forward step fashion, a covariate with the highest
inﬂuence was inserted to the model, followed by other less
signiﬁcant covariates. When such covariate in particular
parametersigniﬁcantly reducedOFV, this covariatewouldbe
retained in the model for further covariate analysis, and vice
versa. However, creatinine clearance by MDRD4 equation
and BUN were excluded in this step, since they had similar
physiologic basis with creatinine clearance by C-G equation.
Additionally, the C-G equation was more widely used in
clinical practice than MDRD4 equation to predict the renal
function of the patients. In case of BUN, although the OFV
was decreased signiﬁcantly from basic model, the value was
much higher than those from C-G and MDRD4 equation,
indicating the less signiﬁcant contribution to the model.
As the result, in forward stepwise, the cumulative inclu-
sion of covariates creatinine clearance by C-G equation on
CL and age on V1 reduced OFV by more than 6.63 at each
addition. These were conﬁrmed by back elimination step.
Accordingly, the model was considered as ﬁnal model of
vancomycin population pharmacokinetics in Thai patients
(Table 2). Further inspection in scatter plot veriﬁed that the
ﬁnal model was better than basic model (two-compartment
model without covariate), as the plots were distributed
closer to the trend-line (Figure 2) and zero line (Figure 3),
respectively.
Sixty-eight vancomycin concentrations from 34 patients
from validation group were used to validate the ﬁnal model.
These observed concentrations were compared with pre-
dicted concentrations calculated from parameters obtained
from the modeling group to determine the predictive
performance. The mean prediction error (ME) as bias4 The Scientiﬁc World Journal
Table 1: Summary of demographic and clinical characteristics of the patients in the modeling group and the validation group.
Characteristics Modeling group Validation group P valuea
Number of patients 212 34 NDb
Total number of vancomycin levels 391 68 NDb
Average number of vancomycin level per patient 1.84 2.00 NDb
Sex distribution Male: 112 (52.83%);
Female: 100 (47.17%)
Male: 12 (35.29%);
Female: 22 (64.71%) 0.058
Age, in years (mean ± SD) 66.62 ±18.38 70.24 ±18.61 0.288
Total body weight, in kg (mean ± SD) 57.64 ±11.62 55.81 ±12.20 0.201
Serum creatinine, in mg/dL (mean ± SD) 3.12 ±2.92 2.70 ±2.81 0.421
Blood urea nitrogen, in mg/dL (mean ± SD) 40.25 ±25.15 46.41 ±40.06 0.410
Creatinine clearance by Cockcroft-Gault equation, in mL/min
(mean ± SD) 35.07 ±29.83 35.50 ±30.61 0.939
Creatinine clearance by MDRD4 equation, in mL/min/1.73m2
(mean ± SD) 44.08 ±36.71 45.36 ±36.43 0.85
Albumin, in g/L (mean ± SD) 25.93 ±7.31 28.79 ±7.53 0.047∗
AST, in U/L (mean ± SD) 87.08 ±177.71 346.52 ±1620.11 0.396
ALT, in U/L (mean ± SD) 83.27 ±157.93 156.17 ±579.60 0.506
Total bilirubin, in mg/dL (mean ± SD) 3.22 ±7.39 1.85 ±4.04 0.329
Direct bilirubin, in mg/dL (mean ± SD) 2.38 ±5.94 1.15 ±2.90 0.074
Ascites (yes/no/unknown) 43/169/0 5/26/3 0.587
Concomittant medication (yes/no/unknown)
Aminoglycosides 27/185/0 1/30/3 0.121
Amphotericin B 12/200/0 0/31/3 0.174
NSAIDs 20/192/0 3/27/4 0.921
Dopamine 33/179/0 2/28/4 0.195
Dobutamine 9/203/0 0/30/4 0.250
Adrenaline/noradrenaline 24/188/0 2/28/4 0.441
Furosemide 77/135/0 15/15/4 0.149
aDiﬀerences between the modeling and validation group were considered to reach statistical signiﬁcance when P<0.05; bNot determined; ∗statistically
signiﬁcant.
0
20
40
60
80
100
120
0 1 02 03 04 05 060
y = 1.134x +7.556
R2 = 0.242
P
r
e
d
i
c
t
e
d
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
L
)
Basic model
Observed concentration (mg/L)
(a)
0
20
40
60
80
100
120
0 1 02 03 04 05 06 0
y = 0.923x +2.779
R2 = 0.609
Final model
P
r
e
d
i
c
t
e
d
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
L
)
Observed concentration (mg/L)
(b)
Figure2:Scatterplotofobservedagainstpredictedconcentrationsinmodelinggroupobtainedfrombasicmodel(two-compartmentmodel,
without covariate) and ﬁnal model (two-compartment model, with covariates).The Scientiﬁc World Journal 5
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Figure 3: Scatter plot of predicted concentrations against weighted residuals in modeling group obtained from basic model (two-
compartment model, without covariate) and ﬁnal model (two-compartment model, with covariates).
Table 2: Population pharmacokinetic parameters of vancomycin in
Thai patients estimated from ﬁnal model.
Parameter Mean estimate Estimation
errora (%)
Fixed parameters
CL (L/h) = θ1 ×CLCr (mL/min)
θ1 0.044 22.34
V1 (L) = θ2 ×Age (years old)
θ2 0.542 16.00
Q (L/h) = θ3
θ3 6.950 45.17
V2 (L) = θ4
θ4 44.200 19.58
Interindividual variability
ωCL (%) 35.78 20.00
ωV1 (%) 20.93 120.00
ωQ (%) 39.50 346.67
ωV2 (%) 57.27 75.47
Intraindividual variability
σ (mg/L) 4.51 38.07
aExpressed as a coeﬃcient of variation.
CL, vancomycin clearance; V1, volume of the central compartment of
vancomycin; Q, vancomycin intercompartmental clearance; V2,v o l u m eo f
the peripheral compartment of vancomycin; CLCr, creatinine clearance
by Cockcroft-Gault equation; ω, interindividual variability related to PK
parameter; σ, intraindividual variability.
measurement was −1.43mg/L with 95% conﬁdence interval
(95% CI) of −5.82–2.99mg/L. Meanwhile, precise measure-
ment as expressed by root mean squared prediction error
(RMSE) with 95% CI was 12.28mg/L (−1.60–26.16mg/L).
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Figure 4: Scatter plot of observed against predicted concentrations
of validation group.
Twoscatterplots(Figures4and5)weretakentodemonstrate
the deviations of predictive and observed concentrations
pairs.
4. Discussion
The present study used a population approach to deter-
mine the pharmacokinetic parameters of vancomycin in
Thai patients along with their inter- and intraindividual
variabilities. Vancomycin was a chosen drug in this study
due to its large pharmacokinetic variabilities. Moreover, the
studies about pharmacokinetic parameters of vancomycin in
Thai population were not available.
Since the renal pathway is the major one for vancomycin
excretion, this is not surprising to elicit creatinine clearance
as signiﬁcant factor for vancomycin clearance. Addition-
ally, the slope of vancomycin clearance-creatinine clearance6 The Scientiﬁc World Journal
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Figure 5: Scatter plot of predicted concentrations against weighted
residuals of validation group.
relationship in the present study (0.044) was very close with
the study in Japanese population (0.048) [15]. The value
of vancomycin clearance using mean value of creatinine
clearance in our study was 1.56L/h. This value was lower
approximately two times than other previous population
studies using similar two-compartment model [4, 15, 16].
The diﬀerence may be due to the lower creatinine clearance
in present population, which accounted about 50% lower
than those populations.
The ﬁnding of increasing V1 in accordance to increasing
age in the present study disagreed with result from other
studyinhealthypopulations[17].Inthatstudy,V1 ofsixmen
with a mean age of 23 years old was not diﬀerent from that of
older six men with a mean age of 68 years old. Diﬀerences of
study population might contribute to this dissimilarity. Age
inﬂuence on V1 does not seem to have direct physiological
basis. Instead, this might be due to age being a surrogate of
illnessseverityorothernonobservedcovariates.Inthisstudy,
the mean of intercompartmental clearance (Q) was slightly
lower than previous studies [4, 15, 16]. It might be caused by
decrease in cardiac output due to their underlying disease of
elderly patients. Decreasing the Q resulted in a more rapid
decrease in plasma concentrations following long infusion
(like in the case of vancomycin administration). Therefore,
the volume of central compartment might be increased as a
net result.
In the present study, V1 and V2 did not associate with
patient’s body weight. The narrow range of body weight
on majority patients (86% of patients’ body weights were
ranged from 40–70kg) might not vary enough to become
a signiﬁcant covariate in this population. Additionally, the
volumeofcentralcompartment(V1)wassigniﬁcantlyrelated
to age. These values (V1:0 . 6 3L / k ga n dV2:0 . 7 7L / k g )s e e m e d
to be larger than previously reported values, particularly in
noncritically ill patients. Hurst et al. found the V1 value of
0.14L/kg in cardiac outpatients who required a single dose
of vancomycin for prophylaxis prior to dental procedure
[18]. Meanwhile, in the study that included patients with
v a r i o u sd e g r e eo fr e n a ld y s f u n c t i o n ,V1 was estimated as
0.21–0.24L/kg [19]. However, when compared with study
in critically ill patients, the values of volume of distribution
in the current study seemed to be smaller, especially in the
value of V2 and volume of distribution at steady state or
VDss (VDss = V1 + V2). In ICU patients, the VDss value of
1.73L/kg was found in the study conducted by Llopis-Salvia
and Jim´ enez-Torres [4]. Using similar pattern of patients,
but with one compartment model, Del Mar Fernandez De
Gatta Gracia et al. got VD of 1.68L/kg [20]. Both are larger
than VDss estimated from our study (1.39L/kg). In the case
of critically ill patients, the increased volume of distribution
was attributed to the sepsis-induced interstitial space ﬂuid
[21]. Type of patients included in the current study as
heterogenous patients (about one third of patients belonged
to ICU patients) might explain why the value of volume
of distribution fell in between those of noncritically ill and
critically ill patients’ values.
Insertion of signiﬁcant covariates to the basic model
decreased the magnitude of interindividual variability, par-
ticularly on parameter of clearance. The %CV of 111.80%
in basic model was decreased to 35.78% after creatinine
clearance was inserted as the covariate in vancomycin clear-
ance. This ﬁnal value is similar to two previous studies using
general Japanese populations (i.e., 38.5% [15] and 37.5%
[6]) but larger than other two speciﬁc-type-based studies [4,
16]. Study in critically ill patients [4]a n dE C M O - s u p p o r t e d
patients [16] demonstrated interindividual variability of
29.2% and 25%, respectively. Interindividual variability for
V1 in the present study (20.93%) was lower than other
two studies (i.e., 25% [16] and 36.4% [4]). However, study
from Yamamoto et al. [6] displayed the decreasing of
interindividual variability of V1 from 18.2% to 10.1% when
type of infectious disease was taking into account. Other two
parameterswithoutcovariate(Q andV2)inthepresentstudy
hadhighervaluesofinterindividualvariabilities(39.50%and
57.27% for interindividual variability for Q and V2,r e s p . ) .
These results suggested that interindividual variabilities
could be aﬀected by other variables that were not assessed
in the present study.
The magnitude of variability in drug concentrations
observed over time within an individual (intraindividual
variability) in the present study was 4.51mg/L. On the
basis of average concentration in this study, which was
17.13mg/L, this equivalent to an average error of 26.32%.
This value was higher than all four previous studies using
similar approach with the present study, which were 23.7%
[15], 13.2% [6], 23.9% [4], and 12.1%± 2.1mg/L [16].
Since the assay error was contributed only less than 5%,
other factors might attribute to this result. For ﬁxed eﬀect
parameters (θn), the degree of imprecision ranged from
4.98% to 28.34%. Furthermore, imprecision of estimating
interindividual variability of parameter of V1 (117.00%)
and Q (158.00%) which represented distribution phase
was higher than values for other two parameters (i.e.,
CL of 22.9% and V2 of 67.68%). Since most samples
were drawn after distribution phase was completed, the
poor precision was expected. Additionally, in the case of
dialysis patients (accounted as 34.43% of total population in
modeling group), rebound phenomenon might be occurred
as sharp decreasing of vancomycin concentration during
haemodialysis session followed by increasing concentration
attheendofhemodialysissessionof3–6hours[22].DrawingThe Scientiﬁc World Journal 7
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Figure 6: Simulation of steady-state vancomycin serum concentra-
tion proﬁle in the 50-year-old patient using dosage regimen of 1
gram/12 hours.
the level during these periods could mislead the result of the
measurement.
Predictive performance in validation step was carried
out by applying the ﬁnal model to the validation group.
The result was not biased and precise, since zero values
were included in the value of ME (representative of bias)
and RMSE (representative of precision) in the 95% CI.
Additionally, the negative value of ME, indicated that the
model under predicted vancomycin concentration.
A scatter plot of predicted concentrations versus
weighted residuals shown the potential outliers, which are
the points outside the ±3 unit range (Figure 5). In this study,
when the data of the covariate in particular day was missing,
the other day data was used. This practice could lead to a
mistake when the true value was signiﬁcantly diﬀerent from
replacing value. The discrepancy between the times (of drug
administration and drawing the samples) happened and was
actually recorded, and also it could not be ignored as the
source of error.
The result from the present study could be used as
basic information in dosage regimen calculation for patients
with similar characteristics as the present study. However,
caution could be drawn in any conditions which were not
accommodated by the present study. For instance, since
there was no body weight included in the model, obese
patients might not be represented by the present model.
Simulation using the result from the present study was
conducted to determine vancomycin serum concentration
when a dosage regimen was applied to particular patient.
Time versus steady-state vancomycin serum concentration
curves in three diﬀerent values of creatinine clearance in
the 50-year-old patient were created (Figure 6). The widely
useddosageregimenofvancomycininnormalrenalfunction
(i.e., 1g every 12 hours) was applied. On the basis of
recent guideline [23], vancomycin trough concentration
above 10mg/L was recommended to avoid development of
resistance. Additionally, vancomycin trough concentration
of 15–20mg/L was desired to treat complicated infec-
tions (endocarditis, osteomyelitis, meningitis, and hospital-
acquired pneumonia). In this simulation, if the patient
had complicated infection, the dose of 1g/12 hours seems
to be suitable for the patients with CLCr of 60mL/min
and 80mL/min. However, in similar circumstances, more
aggressive dose might be needed for the patients with CLCr
of 100mL/min.
In conclusion, the pharmacokinetic parameters of van-
comycininThaipatientsandfactorsinﬂuencingthevariabil-
ity of these pharmacokinetic parameters were established.
Furthermore, the inter- and intraindividual variabilities
of the pharmacokinetic parameters were determined. The
model could be used to obtain the speciﬁc patient’s pharma-
cokinetic parameters to create vancomycin dosage regimen
in the type of patient similar with the present study.
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